Skip to main content

Jones Hill Capital LP

13F filer · CIK 0002102314
Reported Aug 13, 2026
Net seller this quarter
13F portfolio value$470MU.S. long equity reported on 13F
Positions2915 new · 12 closed
Net flow last quarter-$66.1MBuys minus sells
Top 10 positions weight68.8%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 13, 202629 positions
BMRNBiomarin Pharmaceutical Inc$81.9M17.42%0.74%+12.9%Q1 2026
GILDGilead Sciences, Inc.$43.3M9.21%0.03%NewQ2 2026
ARQTArcutis Biotherapeutics, Inc.$28.6M6.07%0.87%NewQ2 2026
MDGLMadrigal Pharmaceuticals, Inc.$28.2M6.00%0.23%NewQ2 2026
BCAXBicara Therapeutics Inc.$26.5M5.63%1.35%-29.2%Q1 2026
RLMDRelmada Therapeutics, Inc.$25.3M5.38%3.43%+966.4%Q1 2026
TRVITrevi Therapeutics, Inc.$25M5.31%0.94%+261.8%Q1 2026
PHVSPharvaris N.V.$23.4M4.98%1.04%+305.9%Q1 2026
XENEXenon Pharmaceuticals Inc.$22.2M4.72%0.38%NewQ2 2026
ANIPAni Pharmaceuticals Inc$19.4M4.11%1.04%-26.6%Q1 2026
IMCRImmunocore Holdings plc$16.3M3.46%1.00%NewQ2 2026
AMLXAmylyx Pharmaceuticals, Inc.$16.1M3.41%0.80%-44.1%Q1 2026
INSMINSMED Inc$13M2.77%0.06%NewQ2 2026
NUVLNuvalent, Inc.$12.2M2.58%3.15%-67.3%Q1 2026
CAPRCapricor Therapeutics, Inc.$10.1M2.15%0.72%-53.7%Q1 2026
ACRSAclaris Therapeutics, Inc.$9.31M1.98%1.26%NewQ2 2026
IMUXImmunic, Inc.$8.3M1.76%3.96%NewQ2 2026
ORICOric Pharmaceuticals, Inc.$8.09M1.72%0.72%NewQ2 2026
TNXPTonix Pharmaceuticals Holding Corp.$7.98M1.70%3.72%+38.3%Q1 2026
SNDXSyndax Pharmaceuticals Inc$7.43M1.58%0.38%NewQ2 2026
OLMAOlema Pharmaceuticals, Inc.$7.18M1.53%0.66%NewQ2 2026
VIRVir Biotechnology, Inc.$6.72M1.43%0.39%-45.0%Q1 2026
CRBPCorbus Pharmaceuticals Holdings, Inc.$6.13M1.30%3.50%NewQ2 2026
DNTHDianthus Therapeutics, Inc.$5.57M1.18%0.10%NewQ2 2026
VRTXVertex Pharmaceuticals Inc / Ma$5.53M1.17%0.00%-89.8%Q1 2026
ELVNEnliven Therapeutics, Inc.$2.53M0.54%0.07%-91.6%Q1 2026
GPCRStructure Therapeutics Inc.$2.18M0.46%0.02%-59.7%Q1 2026
PHATPhathom Pharmaceuticals, Inc.$1.75M0.37%0.20%NewQ2 2026
ACHVAchieve Life Sciences, Inc.$175K0.04%0.03%NewQ2 2026
Q1 2026Reported May 14, 202626 positions
BMRNBiomarin Pharmaceutical Inc$71.7M15.36%0.66%NewQ1 2026
VRTXVertex Pharmaceuticals Inc / Ma$48.5M10.40%0.04%NewQ1 2026
PCVXVaxcyte, Inc.$37.5M8.03%0.45%NewQ1 2026
NUVLNuvalent, Inc.$30.8M6.61%9.61%NewQ1 2026
CAPRCapricor Therapeutics, Inc.$27.6M5.93%1.58%NewQ1 2026
TERNTerns Pharmaceuticals, Inc.$27.5M5.89%0.45%NewQ1 2026
BCAXBicara Therapeutics Inc.$25.1M5.37%1.92%NewQ1 2026
ANIPAni Pharmaceuticals Inc$24.5M5.25%1.42%NewQ1 2026
RAREUltragenyx Pharmaceutical Inc.$24.4M5.23%1.19%NewQ1 2026
ELVNEnliven Therapeutics, Inc.$23.2M4.98%0.97%NewQ1 2026
AMLXAmylyx Pharmaceuticals, Inc.$22.2M4.76%1.44%NewQ1 2026
ARGXArgenx SE$19M4.07%0.04%NewQ1 2026
FULCFulcrum Therapeutics, Inc.$13.6M2.91%2.66%NewQ1 2026
VIRVir Biotechnology, Inc.$10.7M2.30%0.74%NewQ1 2026
NUVBNuvation Bio Inc.$10.2M2.19%0.69%NewQ1 2026
ORKAOruka Therapeutics, Inc.$6.91M1.48%0.28%NewQ1 2026
CTNMContineum Therapeutics, Inc.$6.7M1.44%2.22%NewQ1 2026
MANEVeradermics, Inc$6.37M1.37%0.27%NewQ1 2026
TNXPTonix Pharmaceuticals Holding Corp.$6.22M1.33%3.18%NewQ1 2026
GPCRStructure Therapeutics Inc.$4.85M1.04%0.05%NewQ1 2026
TRDAEntrada Therapeutics, Inc.$4.72M1.01%0.96%NewQ1 2026
PHVSPharvaris N.V.$4.72M1.01%0.26%NewQ1 2026
TRVITrevi Therapeutics, Inc.$4.42M0.95%0.29%NewQ1 2026
RLMDRelmada Therapeutics, Inc.$2.39M0.51%0.33%NewQ1 2026
SLNSilence Therapeutics plc$1.59M0.34%0.21%NewQ1 2026
AVBPArriVent BioPharma, Inc.$1.06M0.23%0.10%NewQ1 2026
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.